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The efflux of cellular cholesterol mediated by apoA-I and ATP-binding cassette transporter A1 (ABCA1) is thought to underlie many of the 
cardiovascular benefits of HDL. Several groups have manufactured apoA-I preparations with the aim of making an infused HDL therapy for the 
acute treatment of atherosclerotic lesions in humans. Here we describe a new formulation of full length human apoA-I termed CSL112 that can be 
produced on commercial scale and that was designed to maximize the ABCA1-dependent efflux. Plasma-derived human apoA-I was combined with 
soy phosphatidylcholine by the cholate dialysis method. Our methods produce disc shaped particles of uniform size. In vitro, CSL112 effectively 
mediated cholesterol efflux from lipid-laden macrophages, and approximately half of the total efflux could be attributed to ABCA1. Immediately after 
infusion of CSL112 into rabbits, the ex vivo cholesterol efflux capacity of rabbit plasma was disproportionately increased: The increase, measured 
in % efflux/mg apoA-I under standardized conditions, was greater than that observed with either CSL112 alone or endogenous rabbit HDL. Native 
gel and Western blot analysis of human apoA-I in rabbit plasma showed that upon infusion, the CSL112 particles were rapidly remodeled first into 
a smaller form and then into larger particles the size of rabbit HDL. The rapid appearance of the low molecular weight particles coincided with 
the rise in the plasma capacity to promote ABCA1-dependent cholesterol efflux. We conclude that CSL112 is a favourable substrate for ABCA1 and 
that remodeling in vivo further raises its ability to mediate ABCA1-dependent efflux. CSL112 may thus provide a novel option for rapid reduction of 
systemic atherosclerotic burden.
